Key Insights

Highlights

Success Rate

75% trial completion

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 47/100

Termination Rate

16.7%

1 terminated out of 6 trials

Success Rate

75.0%

-11.5% vs benchmark

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

133%

4 of 3 completed with results

Key Signals

4 with results75% success

Data Visualizations

Phase Distribution

5Total

Not Applicable (2)

Early P 1 (1)

P 2 (2)

Trial Status

Completed3

Unknown1

Withdrawn1

Terminated1

Trial Success Rate

75.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (6)

Showing 6 of 6 trials

NCT05289648Early Phase 1Withdrawn

Niraparib in High-grade Endometrial Cancer Trial

NCT03681405Not ApplicableCompleted

Supportive Programs for Supporting Optimal Recovery in Participants Undergoing Gynecological Surgery

NCT04114968Unknown

Offering Cervical Cancer Screening to Older Women

NCT03379376Not ApplicableCompleted

EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery

NCT00414076Phase 2Terminated

Letrozole Versus Observation in Patients With Newly Diagnosed Uterine Leiomyosarcoma

NCT00282087Phase 2Completed

Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma

Showing all 6 trials

Uterine Neoplasm